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Abstract
Cancer-related pain is a very prevalent problem in all stages, with 10% of patients requiring 
invasive techniques for adequate pain management. Ganglion impar neurolysis has been used 
in the treatment of pelvic-perineal pain with efficacy and rare complications, but only a few 
case or series reports in cancer patients have been published. We report the case of a patient 
presenting with an ovarian carcinoma (FIGO stage IIIC), who had several disease relapses at 
the colorectal transition and need for palliative colic prosthesis. She presented later with ano-
rectal pain associated with a rectovaginal fistula, which had an important impact on the ac-
tivities of her daily life. She was submitted to two ganglion impar neurolyses, which resulted 
in improved pain control for a total of 5 months, an important improvement in her quality of 
life, and reduction of opioid consumption. The authors aim to alert to the importance of pain 
control and to address the fourth step of the WHO analgesic ladder as an option for cancer 
patients, including palliative patients. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Cancer-related pain is a problem that affects a large proportion of cancer patients. It is 
estimated to be present in approximately 60% of patients undergoing targeted treatment, 
more than 60% of the patients in advanced stages, and more than 30% of the survivors [1, 2]. 
Studies show poor pain control in 56–82% of cases, including patients at the end of life [3, 4]. 
Published online: January 20, 2020
Dr. Filipa Ferreira
Medical Oncology Department, Hospital São Francisco Xavier
Centro Hospitalar de Lisboa Ocidental
Estrada Forte do Alto Duque, PT–1449-005 Lisbon (Portugal)
E-Mail fi_lipaferreira @ hotmail.com
www.karger.com/cro
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 Interna tional License 
(CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial 
purposes requires written permission.
DOI: 10.1159/000505181
30Case Rep Oncol 2020;13:29–34
Ferreira and Pedro: Ganglion Impar Neurolysis in Cancer Pain Management
www.karger.com/cro
© 2020 The Author(s). Published by S. Karger AG, BaselDOI: 10.1159/000505181
Pain is associated with a reduced ability to tolerate treatments, a higher incidence of 
depression, and an important decrease in the quality of life of patients and caregivers [1].
It is estimated that adequate pain control with conventional analgesia is not achieved in 
10–20% of patients. Therefore, invasive procedures (such as neurolytic blocks, locoregional 
anaesthesia or spinal analgesia) were proposed as a fourth step in the analgesic ladder of the 
World Health Organization (WHO) [1]. Its use is advocated by the leading worldwide asso-
ciations of medical oncology and present in clinical guidelines of the European Society of 
Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN), and American 
Society of Clinical Oncology (ASCO) as an option for patients resistant to conventional anal-
gesic therapies or with intolerable adverse effects related to these therapies [4–6]. There is 
increasing evidence of the benefit of these techniques in early cancer stages and they should 
also be considered in survivors with pain which is associated with the targeted treatments 
previously performed and which is difficult to control [2, 4]. They should not be considered 
if it is against the will of the patient, if the life expectancy is very low, or in the case of major 
coagulopathies or infections [1].
Neurolytic blocks consist of the destruction of nervous tissue usually through the injection 
of alcohol at 50–100% or phenol at 6–12%. The coeliac plexus, the superior hypogastric 
plexus, and the ganglion impar are the most common neurolysis sites for the treatment of 
upper abdominal, pelvic, and pelvic-perineal pain, respectively [1, 2]. The ganglion impar, or 
ganglion of Walther, consists of a semi-circular retroperitoneal median structure, anterior to 
the coccyx or the sacrococcygeal junction. Its neural network is formed by several neuro-
logical fibres but it is not yet fully understood: it is believed to include not only the nociceptive 
and sympathetic fibres of the perineum, distal portion of the rectum, anus, distal urethra, 
lower third of the vagina, and vulva/scrotum [1, 2], but also sympathetic branches inner-
vating the pelvic organs [7, 8]. Ganglion impar neurolysis was first described in 1990 by Plan-
carte et al. [9] for the treatment of pain related to perineal cancer. The neurolysis can be 
performed according to four techniques: anococcygeal, coccygeus-transverse, intercoccygeal 
and trans-sacrococcygeal, the latter being the most common. In all techniques, the positioning 
of the needle is confirmed by the injection of radiological contrast by fluoroscopy, followed 
by the administration of local anaesthetics and then the neurolysis with alcohol or phenol [1, 
2]. All techniques can also be guided by ultrasound, tomography or magnetic resonance 
imaging [7, 8]. Pain relief usually lasts for 3–6 months, although the response is variable, 
given tumour burden and nerve regeneration. Complications are rare but may be related to 
local infection or haemorrhage, perforation of the rectum, injection of the periosteum, 
epidural injection, or autonomic/motor dysfunction caused by dispersion of the neurolytic 
substance [1, 2, 8].
Case Report/Case Presentation
The authors present the case of a 75-year-old female patient, diagnosed in 2008 at age 
66, with high-grade bilateral serous ovarian adenocarcinoma with peritoneal carcinomatosis 
at presentation, corresponding to a FIGO (Fédération Internationale de Gynécologie et 
d’Obstétrique) stage IIIC (2014 classification). She initially underwent a total hysterectomy, 
bilateral adnexectomy and omentectomy, and completed adjuvant chemotherapy with pacli-
taxel and carboplatin.
In 2012, the disease relapsed in the rectosigmoid transition, presenting as intestinal sub-
occlusion. Therefore, she was submitted to the endoscopic placement of a colic prosthesis 
(Fig. 1) and palliative chemotherapy with paclitaxel and carboplatin was started, achieving a 
partial response. In 2015, there was new progression of the colonic disease, presenting again 
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with intestinal sub-occlusion, and a new prosthesis was placed. At that time, the patient 
started referring to intermittent anorectal pain that radiated to the lower limbs, with break-
through pain that scored 10/10 on the visual analogue scale. The pain had an important 
neuropathic component described by the patient as a feeling of an electric shock, burning or 
a biting sensation. She also referred to the seated position, certain movements, and intestinal 
elimination as factors of aggravation. Although medicated daily with hydromorphone 32 mg 
and pregabalin 25 mg, with fentanyl sublingual 200 μg as a rescue medication for break-
through pain, she continued to have uncontrolled pain, which had an important impact on her 
daily life. She was then referred to the Pain Unit of the Hospital Prof. Dr. Fernando Fonseca. 
An initial improvement was achieved with an opioid rotation to transdermal fentanyl and a 
combination of corticosteroids, but after a couple of months a constant dose increase was 
needed and soon she was medicated with transdermal fentanyl 175 μg/h associated with 
pregabalin 400 mg/day, prednisolone 20 mg/day, and sublingual fentanyl 400 μg as rescue 
medication.
At the end of 2017, there was a new increase in pain intensity associated with the 
appearance of a rectovaginal fistula. By this time, palliative chemotherapy with cyclophos-
phamide was initiated with good tolerability but no effect on pain control, needing constant 
rescue medication. Since this patient was collaborative, had a good performance status, had 
good family support, and had undergone extremely frequent analgesia adjustments with little 
or no effect, it was suggested to her that she should undergo an invasive technique for pelvic 
and perineal pain management. Therefore, in January 2018, she was submitted to a ganglion 
impar neurolysis guided by fluoroscopy, with the administration of 5 mL of 0.5% levobupi-
vacaine and 3 mL of alcohol at 70%, which was done without problems (Fig. 2, 3). One week 
after the procedure, the patient already reported 10-h periods without pain, tolerance of 
longer periods in a seated position, and improved sleep patterns, with a reduction in the need 
for rescue medication from 9–10 pills of sublingual fentanyl 400 μg per day to 1–2 pills. This 
improvement in pain control was maintained for about 3 months, with an important gain in 
the quality of life. After this period, there was new disease progression and an increase in the 
number of episodes of breakthrough pain per day. Since the patient had benefited before from 
the ganglion impar neurolysis, a second procedure was suggested to her, this time with a 
complementary blockade of the superior hypogastric plexus, which allowed pain control for 
about 2 months. During this time, the patient maintained palliative chemotherapy with cyclo-
phosphamide. She maintained a good quality of life and independence in the activities of her 
daily life till July 2018. At this point there was disease progression refractory to the systemic 
therapy and the patient died in early August.
Fig. 1. Tumour with rectal invasion (arrow) 
and colic prosthesis (dotted arrow).
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Discussion/Conclusion
The available data in the literature suggest that ganglion impar neurolysis is a safe 
procedure with few adverse effects and which is effective in the treatment of pain [1, 7, 8]. It 
has been shown to be effective in the treatment of pelvic pain of malignant or benign origin, 
with most of the studies including patients with different pain aetiologies [7]. Most published 
papers included a follow-up of 2–3 months, showing maintained efficacy of treatment in this 
period in most patients.
Plancarte et al. [9]described reduction of more than 60% of the intensity of perineal pain 
in half of the patients. Several studies have reported cases of patients with pelvic tumours 
with baseline pain relief of 50% or more after the procedure, with reduction of baseline visual 
analogue scale scores of 9–10 to mild pain levels that persist after more than 2 months of 
follow-up and with a significant reduction of opioid use [10–12]. Studies with a longer follow-
up show pain relief durations that reach 3 years [13]. In the largest study with patients 
submitted to this procedure, which included 15 oncology patients from a total of 43, the 
intensity of pain reduction was more prominent in the group with pain of oncological aeti-
Fig. 2. Ganglion impar neurolysis procedure 
part 1: needle placement (circle).
Fig. 3. Ganglion impar neurolysis procedure 
part 2: contrast administration, local anaes-
thetic and alcohol injection (circle).
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ology [14]. Favourable results of combined neurolysis of the ganglion impar and superior 
hypogastric plexus in the reduction of pelvic oncological pain are also reported, since the 
latter includes neural afferent fibres of pelvic viscera [9, 15].
The reported case refers to a cancer patient whose quality of life was significantly affected 
by pelvic-perineal pain, which made it impossible or difficult to perform simple daily tasks. 
Pain control was achieved for 3 months with the first ganglion impar neurolysis, which is 
consistent with the median duration of benefit reported in the literature. The second procedure 
was less effective, but coupled with superior hypogastric plexus neurolysis, it allowed pain 
control for another 2 months. Of note is the significant gain in quality of life, quality of sleep, 
accomplishment of daily tasks, and improvement of social interaction during this period.
With this article the authors aim to alert to the importance of pain control in cancer 
patients and to address the fourth step of the WHO analgesic ladder as an option for these 
patients. The importance of the collaboration between medical oncology departments and 
pain units as a multidisciplinary approach also needs to be emphasized. Invasive techniques 
should be used as part of a multimodal therapy, together with conventional analgesia, in 
order to enhance pain control and decrease possible adverse effects [1, 2, 5]. These tech-
niques might be indicated in palliative patients, as in the case presented, provided that the 
patients are expected to have a benefit in their quality of life with the approach, it is justified 
by their life expectancy, and the risk-benefit is balanced accordingly. Careful patient selection 
as well as control of expectations and appropriate post-procedure care are essential [1].
Statement of Ethics
The authors have no ethical conflicts to disclose. Informed consent was obtained from 
the patients for this report.
Disclosure Statement




Filipa Ferreira is the principal and corresponding author, responsible for the idea of the 
article and its writing. Ana Pedro is the second author, specialized in pain medicine and 
revisor of the article. There are no other contributors.
References
 1 Sindt J, Brogan S. Interventional treatments of cancer pain. Anesthesiology Clin. 2016; 34: 317–39.
 2 Beuken-van Everdingen M, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 
years. Ann Oncol. 2007; 18: 1437–49.
 3 Christo P, Mazloomdoost D. Interventional pain treatments for cancer pain. Ann NY Acad Sci. 2008; 1138: 
299–328.
34Case Rep Oncol 2020;13:29–34
Ferreira and Pedro: Ganglion Impar Neurolysis in Cancer Pain Management
www.karger.com/cro
© 2020 The Author(s). Published by S. Karger AG, BaselDOI: 10.1159/000505181
 4 Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol. 2012; 23(Suppl 7): vii139–vii154.
 5 National Comprehensive Cancer Network. Clinical practice guidelines on adult cancer pain. Version 1. 2018.
 6 Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American 
Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016; 34(27): 3325–45.
 7 Scott-Warren J, Hill V, Rajasekaran A. Ganglion impar blockade: a review. Curr Pain Headache Rep. 2013; 17: 
306.
 8 Gunduz O, Kenis-Coskun O. Ganglion blocks as a treatment of pain: current perspectives. J Pain Res. 2017; 10: 
2815–26.
 9 Plancarte R, et al. Presacral blockade of the ganglion of walther (ganglion impar). Anesthesiology. 1990; 73: 
A751.
10 Toshniwal G, Dureja G, Prashanth S. Transsacrococcygeal approach to ganglion impar block for management 
of chronic perineal pain: a prospective observational study. Pain Phys. 2007; 10: 661–6.
11 Eker H, et al. Transsacrococcygeal approach to ganglion impar for pelvic cancer pain: a report of 3 cases. Reg 
Anesth Pain Med. 2008; 33: 381–2.
12 Bhatnager S, et al. Early ultrasound-guided neurolysis for pain management in gastrointestinal and pelvic 
malignancies: an observational study in a tertiary care center of urban India. Pain Pract. 2012; 12: 23–32.
13 Malec-Milewska M, et al. Neurolytic block of ganglion of Walther for the management of chronic pelvic pain. 
Videosurg Miniinv. 2014; 9(3): 458–62.
14 Agarwal-Kozlowski K, et al. CT-guided blocks and neuroablation of the ganglion impar (Walther) in perineal 
pain: anatomy, technique, safety and efficacy. Clin J Pain. 2009; 25: 570–6.
15 Ahmed D, Mohamad M, Mohamed S. Superior hypogastric plexus combined with ganglion impar neurolytic 
blocks for pelvic and/or perineal cancer pain relief. Pain Phys. 2015; 18: E49–E56.
